Eli Lilly's Tirzepatide Shows Promising Results in MASH Treatment, Fuels Revenue Growth

The biotech giant's innovative compound, tirzepatide, demonstrates significant potential in treating metabolic dysfunction-associated steatohepatitis, contributing to a surge in the company's financial performance.